Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes

Cancer Research

Volumn 58, Issue 10, 1998, Pages 2098-2101

  Evans, James W ^a   Yudoh, Kazuo ^a,b   Delahoussaye, Yvette M ^a   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TIRAPAZAMINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG METABOLISM; DRUG SCREENING; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA, NEOPLASM; FREE RADICALS; HUMANS; LUNG NEOPLASMS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0032523899     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67: 1163-1170, 1993.
2. 2 histography. In: P. W. Vaupel, D. K. Kelleher, and M. Gunderoth (eds.), Tumor Oxygenation, pp. 219-232. Stuttgart, Germany: Gustav Fischer Verlag, 1995.
3. Moulder, J. E., and Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev., 5: 313-341, 1987.
4. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res., 48: 775-778, 1988.
5. Nordsmark, M., Overgaard, M., and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41: 31-40, 1996.
6. Brown, J. M., and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50: 7745-7749, 1990.
7. Done, M. J., and Brown, J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res., 53: 4633-4636, 1993.
8. Lee, D-J., Trotti, A., Spencer, S., Rostock, R., Fisher, C., von Roemeling, R., Harvey, E., and Groves, E. A Phase II trial of radiotherapy with concurrent tirapazamine, a hypoxic cytotoxin, for advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys., in press, 1998.
9. Rodriguez, G. I., Valdivieso, M., Von Hoff, D. D., Kraut, M., Burris, H. A., Eckardt, J. R., Lockwood, G., Kennedy, H., and von Roemeling, R. A Phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC)., Proc. Am. Soc. Clin. Oncol., 15: 382, 1996.
10. Barham, H. M., Patterson, A., Chinje, E. C., Harris, A. L., and Stratford, I. J. Sensitivity to tirapazamine (SR 4233) is determined by P450 reductase activity in human breast but not lung cancer cell lines., Br. J. Cancer, 71 (Suppl. 24): 20, 1995.
11. Elwell, J. H., Siim, B. G., Evans, J. W., and Brown, J. M. Adaptation of human cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity., Biochem. Pharmacol., 54: 249-257, 1997.
12. Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., and Stratford, I. J. Importance of P450 reductase activity in determining sensitivity of breast tumor cells to the bioreductive drug tirapazamine (SR 4233). Br. J. Cancer, 72: 1144-1150, 1995.
13. Bump, E. A., Cerce, B. A., al-Sarraf, R., Pierce, S. M., and Koch, C. J. Radioprotection of DNA in isolated nuclei by naturally occurring thiols at intermediate oxygen tension. Radiat. Res., 132: 94-104, 1992.
14. Koch, C. J., and Giandomenico, A. R. The alkaline elution technique for measuring DNA single strand breaks: increased reliability and sensitivity. Anal. Biochem., 220: 58-65, 1994.
15. Baker, M. A., Zeman, E. M., Hirst, V. K., and Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res., 48: 5947-5952, 1988.
16. Brown, J. M. Redox activation of benzotriazine N-oxides: mechanisms and potential as anticancer drugs. In: G. E. Adams, A. Breccia, E. M. Fielden, and P. Wardman (eds.), Selective Activation of Drugs by Redox Processes, pp. 137-148. New York: Plenum Press, 1991.
17. Warters, R. L., and Lyons, B. W. Variation in radiation-induced formation of DNA double-strand breaks as a function of chromatin structure. Radiat. Res., 130: 309-318, 1992.
18. Olive, P. L. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine. Br. J. Cancer, 71: 529-536, 1995.
19. Wang, J., Biedermann, K. A., and Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 52: 4473-4477, 1992.
20. Bedford, J. S., and Goodhead, D. T. Breakage of human interphase chromosomes by a particles and X-rays. Int. J. Radiat. Biol., 55: 211-216, 1989.